Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ranbaxy Claims Greatest Indian Market Share, Ahead of Cipla, GSK

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy Laboratories beat out Cipla as India's drug maker with the highest share of the domestic market in July. Ranbaxy claimed a 5.1 percent market share during the month, while Cipla recorded a 4.89 percent share. Ranbaxy's sales for the month increased by 13.4 percent compared with Cipla's 9.7 percent. The audit by ORG-IMS gave U.K. drug maker GlaxoSmithKline the third largest market share, followed by Indian makers Piramal Healthcare and Zydus Cadila. (Click here for more

You may also be interested in...



GSK To Take Second Shot At The Rural Indian Market; Considering Customized Strategy

MUMBAI - India's largest multinational drug maker GlaxoSmithKline is planning a big entry into the country's rural pharmaceutical market. An exhaustive plan is being hammered out to understand the dynamics of the rural medicine market so that GSK can position itself correctly in the intensely price-sensitive market segment

BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals

Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.

Boston Scientific TheraSphere Liver Cancer Treatment Succeeds In EPOCH Trial

Results showed that patients were less likely to exhibit disease progression, or die, following treatment with beta-emitted microspheres.

UsernamePublicRestriction

Register

SC069511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel